Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't buy the calls, extremely illiquid on these.
Sup homie calls here been mega $$$$$$ and agree a lot more coming..
Must be a good reason for the sp to drop that much
Fantastic move these past couple of weeks, definitely more to come, a lot more.
Yeppers, no doubt... Monster day
A couple of days like today and we’ll be there pretty fast
Heading towards $100
They’d be negligent not to.
Covavax’s efficacy is TIGHT, but consider the rest of the pipeline too!
Read The Mosquito by Dr. Timothy C. Winegard and you’ll realize the global and historical significance of Novavax’s malaria vaccine when standard pharmaceuticals are beginning to lose their edge.
https://www.biopharma-reporter.com/Article/2021/04/26/Malaria-vaccine-candidate-first-to-reach-WHO-goal-with-77-efficacy
NanoFlu has bested High Dose FluZone in trials.
https://www.fiercebiotech.com/biotech/novavax-flu-vaccine-matches-and-beats-sanofi-rival-phase-3
Thus far Novavax’s RSV candidate is still the best in its class considering the current standard is palliative care.
Novavax is simply THE powerhouse delivering the goods.
Will fda approve?
Heck yeah…
News Issued: Jul 1, 2022 (12:46pm EDT)
To view this online and get more information about Novavax Investor Relations visit: https://ir.novavax.com/Novavax-Statement-on-Prototype-Vaccines-Broad-Immune-Responses-and-Accelerated-Focus-on-Omicron-BA-4-5-as-Recommended-by-the-FDA
Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA
Well of course the dinosaur was pumping
Looks like I need to put a few more PM's out on Twitter for a few laughs
See what I mean about personal attacks when you know you're 1000% wrong..
I know you so well..looser.
Who cares stop patting yourself on the back with your trades over the last five years Dear God..
Like I said....you called for HOY I can't wait till the end of June..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169002304
Riding on 30,000 shares at 1.40 doubled my money today. AUV*I
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169081277
I'm so looking forward to the end of June..
Wink
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169002304
I care, I am in this for the long haul. That is why I didn't go too heavy on this, otherwise I would have easily bought 50,000 shares instead of 4000 and then added along the way to the tune of 6000. I will continue to add everyday 200-400 shares.
Nobody cares about what happens a year from now...
You know this
I am not concerned with NVA*X the 13th is the day. This is where my average is, NVAX will make 25 dollar EPS by end of next year.
Nobody said $300, did you hear that from me?
So you’re basically saying my answer is correct lol.
So you’re basically saying my answer is correct lol. Nobody said $300, did you hear that from me? Don’t think so
$100 definitely doable
I don’t use dumb terms like that, but will go higher than where it’s sits now. Easy answer
I don’t use dumb terms like that, but will go higher than where it’s sits now. Easy answer
So if this gets EUA... she should fly to the moon right?
Your right!!! ;)
There is a way, amateurs
High short interest combined with under 50% institutional ownership equals shenanigans in the stock price. The shorts will be allowed to cover and the big guys will get onboard. I know it sounds jaded but I've seen it time and time again. If you believe the revenue will be solid it's way undervalued.
best to all,
eastcoastguy
Totally normal, this wil
Close above $55 today
To many fda approved drugs
W o w
The phuckery is has started early today.
The market corruption is boundless.
S M H
Novavax Covid Vaccine Could Soon Win EUA Approval — And So What?
https://www.tipranks.com/news/article/novavax-covid-vaccine-could-soon-win-eua-approval-and-so-what?utm_source=advfn.com&utm_medium=referral
Why you think that
looks some no like $MRNA offers new solution $nvax
$NVAX Received its Third Buy in a Row
June 08 2022 - 07:05AM
After Cantor Fitzgerald and H.C. Wainwright gave Novavax (NASDAQ: NVAX) a Buy rating last month, the company received another Buy, this time from B.Riley Financial. Analyst Mayank Mamtani reiterated a Buy rating on Novavax today and set a price target of $181.00. The company's shares closed last Monday at $47.54, close to its 52-week low of $41.10. According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of -32.2% and a 21.3% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
https://www.tipranks.com/news/blurbs/novavax-nvax-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral
Followers
|
338
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
8537
|
Created
|
06/19/03
|
Type
|
Free
|
Moderators mick JoeForkeyBolo |
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Using innovative proprietary recombinant nanoparticle vaccine technology,
we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. More...
INVESTORS
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease. More...
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |